Athyrium Capital Management, LP - Q1 2022 holdings

$281 Million is the total value of Athyrium Capital Management, LP's 10 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .

 Value Shares↓ Weighting
 Progenity Inc.note 7.250% 12/0$73,701,000
-2.3%
103,500,0000.0%26.20%
-2.5%
AMYT  Amryt Pharma PLCsponsored ads$73,250,000
-23.4%
8,857,2680.0%26.04%
-23.6%
PROG  Progenity Inc.$34,633,000
-44.5%
29,855,8470.0%12.31%
-44.7%
OSMT  RVL PHARMACEUTICALS PLC$13,772,000
+56.5%
8,148,8320.0%4.90%
+56.0%
REPH  Societal CDMO Inc.$3,964,000
+5.3%
2,202,4200.0%1.41%
+4.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Amryt Pharma PLC10Q1 202346.3%
Progenity Inc.9Q4 202269.2%
Progenity Inc.8Q3 202339.2%
RVL PHARMACEUTICALS PLC8Q3 202311.5%
Societal CDMO Inc.8Q4 20223.1%
Omeros Corp7Q3 202339.3%
CAREMAX INC7Q4 202227.5%
Omeros Corp7Q3 20239.9%
PUMA BIOTECHNOLOGY INC7Q3 20234.2%
AEGERION PHARMACEUTICALS INC6Q1 201988.7%

View Athyrium Capital Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Athyrium Capital Management, LP Q1 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
PROGENITY, INC.August 27, 20214,211,9772.7%

View Athyrium Capital Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-16
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR/A2023-05-16
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16

View Athyrium Capital Management, LP's complete filings history.

Compare quarters

Export Athyrium Capital Management, LP's holdings